Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOX-anchored biotinylated Cetuximab

Oncotarget

Volumn 5, Issue 19, 2014, Pages 9239-9255

  De Santis, Rita ^a   Rosi, Antonio ^a   Anastasi, Anna Maria ^a   Chiapparino, Caterina ^a   Albertoni, Claudio ^a   Leoni, Barbara ^a   Pelliccia, Angela ^a   Santapaola, Daniela ^a   Carollo, Valeria ^a   Marra, Emanuele ^b   Aurisicchio, Luigi ^b   Arseni, Brunilde ^b   Pacello, Maria Lucrezia ^b   Palmieri, Gabriella ^c   Battella, Simone ^c   Petronzelli, Fiorella ^a   Milazzo, Ferdinando Maria ^a  

^a Sigma Tau SpA   (Italy)

^b Via di Castel Romano   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Aerosol; AvidinOX; Cetuximab; Lung cancer

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; ARTIFICIAL RECEPTOR; AVIDINOX; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PANITUMUMAB; RITUXIMAB; UNCLASSIFIED DRUG; AVIDIN; EGFR PROTEIN, MOUSE; MONOCLONAL ANTIBODY;

A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOTINYLATION; CANCER INHIBITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIMERIZATION; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; ENDOCYTOSIS; FEMALE; HUMAN; HUMAN CELL; LUNG CANCER; MOUSE; NEBULIZATION; NONHUMAN; NUDE MOUSE; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; ACTIVE TRANSPORT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; LUNG NEOPLASMS; LYSOSOME; METABOLISM; PATHOLOGY; PROTEIN MULTIMERIZATION;

ACTIVE TRANSPORT, CELL NUCLEUS; ADMINISTRATION, INHALATION; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; AVIDIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CETUXIMAB; ENDOCYTOSIS; HUMANS; LUNG NEOPLASMS; LYSOSOMES; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; PROTEIN MULTIMERIZATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84910049818     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2409     Document Type: Article

References (50)

1. Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic Burden of Cancer Across the European Union: a Population-Based Cost Analysis. Lancet Oncol. 2013; 14(12):1165-1174.
2. Douillard JY, Pirker R, O'Byrne KJ, Kerr KM, Storkel S, von Heydebreck A, Grote HJ, Celik I, Shepherd FA. Relationship Between EGFR Expression, EGFR Mutation Status, and the Efficacy of Chemotherapy Plus Cetuximab in FLEX Study Patients With Advanced Non-Small-Cell Lung Cancer. J Thorac Oncol. 2014; 9(5):717-724.
3. Pujol JL, Pirker R, Lynch TJ, Butts CA, Rosell R, Shepherd FA, Vansteenkiste J, O'Byrne KJ, de Blas B, Heighway J, von Heydebreck A, Thatcher N. Meta-Analysis of Individual Patient Data From Randomized Trials of Chemotherapy Plus Cetuximab As First-Line Treatment for Advanced Non-Small Cell Lung Cancer. Lung Cancer. 2014; 83(2):211-218.
4. Villanueva MT. Lung Cancer: Cetuximab, You'Re Fired. Nat Rev Clin Oncol. 2014; 11(1):3.
5. Darwiche K, Zarogoulidis P, Karamanos NK, Domvri K, Chatzaki E, Constantinidis TC, Kakolyris S, Zarogoulidis K. Efficacy Versus Safety Concerns for Aerosol Chemotherapy in Non-Small-Cell Lung Cancer: a Future Dilemma for Micro-Oncology. Future Oncol. 2013; 9(4):505-525.
6. Densmore CL. The Re-Emergence of Aerosol Gene Delivery: a Viable Approach to Lung Cancer Therapy. Curr Cancer Drug Targets. 2003; 3(4):275-286.
7. Maillet A, Guilleminault L, Lemarie E, Lerondel S, Azzopardi N, Montharu J, Congy-Jolivet N, Reverdiau P, Legrain B, Parent C, Douvin DH, Hureaux J, Courty Y, De Monte M, Diot P, Paintaud G, et al. The Airways, a Novel Route for Delivering Monoclonal Antibodies to Treat Lung Tumors. Pharm Res. 2011; 28(9):2147-2156.
8. Verdoliva A, Bellofiore P, Rivieccio V, Catello S, Colombo M, Albertoni C, Rosi A, Leoni B, Anastasi AM, De Santis R. Biochemical and Biological Characterization of a New Oxidized Avidin With Enhanced Tissue Binding Properties. J Biol Chem. 2010; 285(12):9090-9099.
9. Nucera E, Nicoletti C, Chiapparino C, Pacello ML, D'Alessio V, Musaro A, De Santis R. AvidinOX for Tissue Targeted Delivery of Biotinylated Cells. Int J Immunopathol Pharmacol. 2012; 25(1):239-246.
10. De Santis R, Anastasi AM, Pelliccia A, Rosi A, Albertoni C, Verdoliva A, Petronzelli F, D'Alessio V, Serani S, Nuzzolo CA. Chemical Linkage to Injected Tissues Is a Distinctive Property of Oxidized Avidin. PLoS One. 2011; 6(6):e21075.
11. De Santis R, Albertoni C, Rosi A, Leoni B, Petronzelli F, D'Alessio V, Nucera E, Salvatori G, Paganelli G, Verdoliva A, Carminati P, Nuzzolo CA. OXavidin for Tissue Targeting Biotinylated Therapeutics. J Biomed Biotechnol. 2009; ID:921434.
12. De Santis R, Leoni B, Rosi A, Albertoni C, Forni G, Cojoca R, Iezzi M, Musiani P, Paganelli G, Chinol M, Carminati P. AvidinOX for Highly Efficient Tissue-Pretargeted Radionuclide Therapy. Cancer Biother Radiopharm. 2010; 25(2):143-148.
13. Urbano N, Papi S, Ginanneschi M, De Santis R, Pace S, Lindstedt R, Ferrari L, Choi S, Paganelli G, Chinol M. Evaluation of a New Biotin-DOTA Conjugate for Pretargeted Antibody-Guided Radioimmunotherapy (PAGRIT). Eur J Nucl Med Mol Imaging. 2007; 34(1):68-77.
14. Kim KJ, Malik AB. Protein Transport Across the Lung Epithelial Barrier. Am J Physiol Lung Cell Mol Physiol. 2003; 284(2):L247-259.
15. Maillet A, Congy-Jolivet N, Le GS, Vecellio L, Hamard S, Courty Y, Courtois A, Gauthier F, Diot P, Thibault G, Lemarié E, Heuzé-Vourc'h N. Aerodynamical, Immunological and Pharmacological Properties of the Anticancer Antibody Cetuximab Following Nebulization. Pharm Res. 2008; 25(6):1318-1326.
16. Petronzelli F, Pelliccia A, Anastasi AM, D'Alessio V, Albertoni C, Rosi A, Leoni B, De Angelis C, Paganelli G, Palombo G, Dani M, Carminati P, De Santis R. Improved Tumor Targeting by Combined Use of Two Antitenascin Antibodies. Clin Cancer Res. 2005; 11(19 Pt 2):7137s-7145s.
17. Petronzelli F, Anastasi AM, Pelliccia A, Santapaola D, Albertoni C, Rosi A, Leoni B, Ferrari L, Paganelli G, Gramiccioli G, Pesce D, Alfano AM, Stasi MA, De Santis R. Preclinical Pharmacology and Safety of a Novel Avidin Derivative for Tissue-Targeted Delivery of Radiolabelled Biotin. Basic Clin Pharmacol Toxicol. 2011; 109(3):145-155.
18. Seo Y, Ishii Y, Ochiai H, Fukuda K, Akimoto S, Hayashida T, Okabayashi K, Tsuruta M, Hasegawa H, Kitagawa Y. Cetuximab-Mediated ADCC Activity Is Correlated With the Cell Surface Expression Level of EGFR but Not With the KRAS/BRAF Mutational Status in Colorectal Cancer. Oncol Rep. 2014; 31(5):2115-2122.
19. Lemmon MA, Schlessinger J, Ferguson KM. The EGFR Family: Not So Prototypical Receptor Tyrosine Kinases. Cold Spring Harb Perspect Biol. 2014; 6(4):a020768.
20. Liao HJ, Carpenter G. Cetuximab/C225-Induced Intracellular Trafficking of Epidermal Growth Factor Receptor. Cancer Res. 2009; 69(15):6179-6183.
21. Gong H, Kovar JL, Cheung L, Rosenthal EL, Olive DM. A Comparative Study of Affibody, Panitumumab, and EGF for Near-Infrared Fluorescence Imaging of EGFR-and EGFRvIII-expressing tumors. Cancer Biol Ther. 2014; 15(2):185-193.
22. Roskoski R, Jr. The ErbB/HER Family of Protein-Tyrosine Kinases and Cancer. Pharmacol Res. 2014; 79:34-74.
23. Liu RY, Zeng Y, Lei Z, Wang L, Yang H, Liu Z, Zhao J, Zhang HT. JAK/STAT3 Signaling Is Required for TGF-Beta-Induced Epithelial-Mesenchymal Transition in Lung Cancer Cells. Int J Oncol. 2014; 44(5):1643-1651.
24. Tomas A, Futter CE, Eden ER. EGF Receptor Trafficking: Consequences for Signaling and Cancer. Trends Cell Biol. 2014; 24(1):26-34.
25. Wang YN, Hung MC. Nuclear Functions and Subcellular Trafficking Mechanisms of the Epidermal Growth Factor Receptor Family. Cell Biosci. 2012; 2(1):13.
26. Alexander DJ, Collins CJ, Coombs DW, Gilkison IS, Hardy CJ, Healey G, Karantabias G, Johnson N, Karlsson A, Kilgour JD, McDonald P. Association of Inhalation Toxicologists (AIT) Working Party Recommendation for Standard Delivered Dose Calculation and Expression in Non-Clinical Aerosol Inhalation Toxicology Studies With Pharmaceuticals. Inhal Toxicol. 2008; 20(13):1179-1189.
27. Ledon N, Casaco A, Casanova E, Beausoleil I. Comparative Analysis of Binding Affinities to Epidermal Growth Factor Receptor of Monoclonal Antibodies Nimotuzumab and Cetuximab Using Different Experimental Animal Models. Placenta. 2011; 32(7):531-534.
28. Fojo T, Grady C. How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question. J Natl Cancer Inst. 2009; 101(15):1044-1048.
29. Rossi A. Cetuximab and Non-Small-Cell Lung Cancer: End of the Story? Lancet Oncol. 2013; 14(13):1251-1253.
30. Crawford J, Swanson P, Schwarzenberger P, Sandler A, Prager D, Zhang K, Freeman DJ, Johnson CW, Krishnan K, Johnson D. A Phase 2 Randomized Trial of Paclitaxel and Carboplatin With or Without Panitumumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Thorac Oncol. 2013; 8(12):1510-1518.
31. Antonyak MA, Cerione RA. Microvesicles as mediators of intercellular communication in cancer. Methods Mol Biol. 2014; 1165:147-173.
32. Petronzelli F, Pelliccia A, Anastasi AM, Lindstedt R, Manganello S, Ferrari LE, Albertoni C, Leoni B, Rosi A, D'Alessio V, Deiana K, Paganelli G, De Santis R. Therapeutic Use of Avidin Is Not Hampered by Antiavidin Antibodies in Humans. Cancer Biother Radiopharm. 2010; 25(5):563-570.
33. Voigt M, Braig F, Gothel M, Schulte A, Lamszus K, Bokemeyer C, Binder M. Functional Dissection of the Epidermal Growth Factor Receptor Epitopes Targeted by Panitumumab and Cetuximab. Neoplasia. 2012; 14(11):1023-1031.
34. Casaletto JB, McClatchey AI. Spatial Regulation of Receptor Tyrosine Kinases in Development and Cancer. Nat Rev Cancer. 2012; 12(6):387-400.
35. Iida M, Brand TM, Campbell DA, Li C, Wheeler DL. Yes and Lyn Play a Role in Nuclear Translocation of the Epidermal Growth Factor Receptor. Oncogene. 2013; 32(6):759-767.
36. Brand TM, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, Wleklinski MJ, Yang D, Wisinski KB, Salgia R, Wheeler DL. Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer. Mol Cancer Ther. 2014; 13(5):1356-1368.
37. Ryu SH, Lee SW, Yang YJ, Song SY, Kim JH, Choi EK, Ahn SD. Intracytoplasmic Epidermal Growth Factor Receptor Shows Poor Response to the Cetuximab Antitumor Effect in Irradiated Non-Small Cell Lung Cancer Cell Lines. Lung Cancer. 2012; 77(3):482-487.
38. Huang WC, Chen YJ, Li LY, Wei YL, Hsu SC, Tsai SL, et al. Nuclear Translocation of Epidermal Growth Factor Receptor by Akt-Dependent Phosphorylation Enhances Breast Cancer-Resistant Protein Expression in Gefitinib-Resistant Cells. J Biol Chem. 2011; 286(23):20558-20568.
39. Brand TM, Iida M, Luthar N, Starr MM, Huppert EJ, Wheeler DL. Nuclear EGFR As a Molecular Target in Cancer. Radiother Oncol. 2013; 108(3):370-377.
40. Sousa LP, Lax I, Shen H, Ferguson SM, De Camilli P, Schlessinger J. Suppression of EGFR Endocytosis by Dynamin Depletion Reveals That EGFR Signaling Occurs Primarily at the Plasma Membrane. Proc Natl Acad Sci U S A 2012; 109(12):4419-4424.
41. Du Y, Shen J, Hsu JL, Han Z, Hsu MC, Yang CC, Kuo HP, Wang YN, Yamaguchi H, Miller SA, Hung MC. Syntaxin 6-Mediated Golgi Translocation Plays an Important Role in Nuclear Functions of EGFR Through Microtubule-Dependent Trafficking. Oncogene. 2014; 33(6):756-770.
42. Wang YN, Lee HH, Lee HJ, Du Y, Yamaguchi H, Hung MC. Membrane-Bound Trafficking Regulates Nuclear Transport of Integral Epidermal Growth Factor Receptor (EGFR) and ErbB-2. J Biol Chem. 2012; 287(20):16869-16879.
43. Luwor RB, Chin X, McGeachie AB, Robinson PJ, Zhu HJ. Dynamin II Function Is Required for EGF-Mediated Stat3 Activation but Not Erk1/2 Phosphorylation. Growth Factors. 2012; 30(4):220-229.
44. Galperin E, Sorkin A. Endosomal Targeting of MEK2 Requires RAF, MEK Kinase Activity and Clathrin-Dependent Endocytosis. Traffic. 2008; 9(10):1776-1790.
45. Tanizaki J, Okamoto I, Sakai K, Nakagawa K. Differential Roles of Trans-Phosphorylated EGFR, HER2, HER3, and RET As Heterodimerisation Partners of MET in Lung Cancer With MET Amplification. Br J Cancer. 2011; 105(6):807-813.
46. Gibault L, Cazes A, Narjoz C, Blons H. Molecular Profiling of Non-Small Cell Lung Cancer. Rev Pneumol Clin. 2014; 70(1-2):47-62.
47. Posch C, Weihsengruber F, Bartsch K, Feichtenschlager V, Sanlorenzo M, Vujic I, Monshi B, Ortiz-Urda S, Rappersberger K. Low-Dose Inhalation of Interleukin-2 Bio-Chemotherapy for the Treatment of Pulmonary Metastases in Melanoma Patients. Br J Cancer. 2014; 110(6):1427-1432.
48. Shimanovsky A, Dasanu CA. Updates on Immunotherapy in Non-Small Cell Lung Cancer. Expert Opin Biol Ther. 2014; 14(4):411-418.
49. Panosa C, Tebar F, Ferrer-Batalle M, Fonge H, Seno M, Reilly RM, et al. Development of an Epidermal Growth Factor Derivative With EGFR Blocking Activity. PLoS One. 2013; 8(7):e69325.
50. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving Bioscience Research Reporting: the ARRIVE Guidelines for Reporting Animal Research. Osteoarthritis Cartilage. 2012; 20(4):256-260.